Genetically engineered antibodies and their application to brain delivery

Sherie L. Morrison, Seung-Uon Shin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Techniques of genetic engineering and expression have been applied to the production of antibodies in a variety of expression systems. Combinatorial libraries produced in bacteriophage may present an alternative to animal immunization as a source of antigen-binding specificities. Transfectomas which express genetically engineered antibody genes provide one approach to overcoming some of the limitations inherent in classical monoclonal antibodies. Novel antibodies have been produced with a variety of modifications: as chimeric antibodies, as 'humanized' antibodies, with catalytic groups, as bifunctional or fusion proteins and as functional fragments such as Fabs or Fvs. The domain structure of the antibody is favorable to such manipulation; the novel proteins often retain their antibody-derived activity and acquire new properties as well. Chimeric and CDR-grafted antibodies have been effective in immunotherapy, but problems of immunogenicity remain. Careful analysis and comparison of effector functions among immunoglobulin isotypes may be applied to the design of effective therapeutic antibodies. In addition, antibody combining specificities can be joined with non-immunoglobulin sequences thereby providing properties not usually found in antibodies. In particular, antibodies fused with the growth factors insulin-like growth factor(IGF)-1, IGF-2 and transferrin have shown increased uptake into the brain parenchyma. These fusion proteins provide a family of reagents with many potential applications.

Original languageEnglish
Pages (from-to)147-175
Number of pages29
JournalAdvanced Drug Delivery Reviews
Volume15
Issue number1-3
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Antibodies
Brain
Somatomedins
Antibodies, Monoclonal, Humanized
Proteins
Genetic Engineering
Antibody Specificity
Immunoglobulin Isotypes
Transferrin
Bacteriophages
Immunotherapy
Antibody Formation
Immunization
Intercellular Signaling Peptides and Proteins
Monoclonal Antibodies
Antigens
Genes
Therapeutics

Keywords

  • Antibody-growth factor fusion protein
  • Bifunctional antibody
  • Chimeric antibody
  • Combinatorial library
  • Effector function

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Genetically engineered antibodies and their application to brain delivery. / Morrison, Sherie L.; Shin, Seung-Uon.

In: Advanced Drug Delivery Reviews, Vol. 15, No. 1-3, 01.01.1995, p. 147-175.

Research output: Contribution to journalArticle

@article{24d564529ea04c17bda441888b05c5b4,
title = "Genetically engineered antibodies and their application to brain delivery",
abstract = "Techniques of genetic engineering and expression have been applied to the production of antibodies in a variety of expression systems. Combinatorial libraries produced in bacteriophage may present an alternative to animal immunization as a source of antigen-binding specificities. Transfectomas which express genetically engineered antibody genes provide one approach to overcoming some of the limitations inherent in classical monoclonal antibodies. Novel antibodies have been produced with a variety of modifications: as chimeric antibodies, as 'humanized' antibodies, with catalytic groups, as bifunctional or fusion proteins and as functional fragments such as Fabs or Fvs. The domain structure of the antibody is favorable to such manipulation; the novel proteins often retain their antibody-derived activity and acquire new properties as well. Chimeric and CDR-grafted antibodies have been effective in immunotherapy, but problems of immunogenicity remain. Careful analysis and comparison of effector functions among immunoglobulin isotypes may be applied to the design of effective therapeutic antibodies. In addition, antibody combining specificities can be joined with non-immunoglobulin sequences thereby providing properties not usually found in antibodies. In particular, antibodies fused with the growth factors insulin-like growth factor(IGF)-1, IGF-2 and transferrin have shown increased uptake into the brain parenchyma. These fusion proteins provide a family of reagents with many potential applications.",
keywords = "Antibody-growth factor fusion protein, Bifunctional antibody, Chimeric antibody, Combinatorial library, Effector function",
author = "Morrison, {Sherie L.} and Seung-Uon Shin",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/0169-409X(95)00008-U",
language = "English",
volume = "15",
pages = "147--175",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Genetically engineered antibodies and their application to brain delivery

AU - Morrison, Sherie L.

AU - Shin, Seung-Uon

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Techniques of genetic engineering and expression have been applied to the production of antibodies in a variety of expression systems. Combinatorial libraries produced in bacteriophage may present an alternative to animal immunization as a source of antigen-binding specificities. Transfectomas which express genetically engineered antibody genes provide one approach to overcoming some of the limitations inherent in classical monoclonal antibodies. Novel antibodies have been produced with a variety of modifications: as chimeric antibodies, as 'humanized' antibodies, with catalytic groups, as bifunctional or fusion proteins and as functional fragments such as Fabs or Fvs. The domain structure of the antibody is favorable to such manipulation; the novel proteins often retain their antibody-derived activity and acquire new properties as well. Chimeric and CDR-grafted antibodies have been effective in immunotherapy, but problems of immunogenicity remain. Careful analysis and comparison of effector functions among immunoglobulin isotypes may be applied to the design of effective therapeutic antibodies. In addition, antibody combining specificities can be joined with non-immunoglobulin sequences thereby providing properties not usually found in antibodies. In particular, antibodies fused with the growth factors insulin-like growth factor(IGF)-1, IGF-2 and transferrin have shown increased uptake into the brain parenchyma. These fusion proteins provide a family of reagents with many potential applications.

AB - Techniques of genetic engineering and expression have been applied to the production of antibodies in a variety of expression systems. Combinatorial libraries produced in bacteriophage may present an alternative to animal immunization as a source of antigen-binding specificities. Transfectomas which express genetically engineered antibody genes provide one approach to overcoming some of the limitations inherent in classical monoclonal antibodies. Novel antibodies have been produced with a variety of modifications: as chimeric antibodies, as 'humanized' antibodies, with catalytic groups, as bifunctional or fusion proteins and as functional fragments such as Fabs or Fvs. The domain structure of the antibody is favorable to such manipulation; the novel proteins often retain their antibody-derived activity and acquire new properties as well. Chimeric and CDR-grafted antibodies have been effective in immunotherapy, but problems of immunogenicity remain. Careful analysis and comparison of effector functions among immunoglobulin isotypes may be applied to the design of effective therapeutic antibodies. In addition, antibody combining specificities can be joined with non-immunoglobulin sequences thereby providing properties not usually found in antibodies. In particular, antibodies fused with the growth factors insulin-like growth factor(IGF)-1, IGF-2 and transferrin have shown increased uptake into the brain parenchyma. These fusion proteins provide a family of reagents with many potential applications.

KW - Antibody-growth factor fusion protein

KW - Bifunctional antibody

KW - Chimeric antibody

KW - Combinatorial library

KW - Effector function

UR - http://www.scopus.com/inward/record.url?scp=0029057209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029057209&partnerID=8YFLogxK

U2 - 10.1016/0169-409X(95)00008-U

DO - 10.1016/0169-409X(95)00008-U

M3 - Article

AN - SCOPUS:0029057209

VL - 15

SP - 147

EP - 175

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

IS - 1-3

ER -